Pipeline Assessment

Expanding Into Asia-Pacific: Life sciences opportunities and strategies for success
Objective :

Assessment of pipeline activities around client’s area of interest to support strategic decisions

Problem Statement:

A medium pharmaceutical client based in the United States with capabilities in cancer immunotherapy domain involved DelveInsight to analyze current pipeline activity of T-Cell Receptor (TCR) products for cancer treatment. They wished to identify currently active T-Cell Receptor (TCR) products in research and development for cancer treatment.

Our Methodology:
  • Detailed Assessment of pipeline activity of T-Cell Receptor (TCR) products
  • Clinical Trial Assessment of Clinical Stage products of T-Cell Receptor (TCR) arena
  • Company Assessment via Funding/Collaboration/Partnership Analysis
  • Analyst Comments on R&D developments
Results:
  • Detailed pipeline profiles of T-Cell Receptor (TCR) products
  • Additional comments on Inactive (Discontinued and Dormant) products.
  • Therapeutic assessment of active pipeline products
  • Detailed profiles of Companies with key coverage of collaboration/partnering activities

Related Insights

Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio, and was interested to assess best possible asset for atrial fibrillation [...]

View Case
Regulatory Analysis
Regulatory Analysis

A large client based in Europe, involved in Dermatology arena with a market-ready product, aimed to assess the Indian Regulatory Scenario to successfully file the product in CDSCO. [...]

View Case
Competitive Intelligence
Competitive Intelligence

A large client based in Europe involved DelveInsight to assist in assessing counter-intelligence strategies for them, after evaluation of their level of leakiness among middle and high-level employees. [...]

View Case

Fill the form to download the case study

I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.